Abstract. Alzheimer's disease (AD) is a central nervous system disorder pathologically characterized by senile plaques, neurofibrillary tangles, and synapse loss. A small percentage of individuals with normal antemortem psychometric scores, after adjustments for age and education, meet the neuropathological criteria for amnestic mild cognitive impairment (MCI) or AD; these individuals have been termed 'preclinical' or 'asymptomatic' AD (PCAD). In this study, we employed the immunochemical slot-blot method and two-dimensional gel-based redox proteomics to observe differences in protein levels and oxidative modifications between groups with equal levels of AD pathology who differ in regards to clinical symptoms of memory impairment. Results of global oxidative stress measurements revealed significantly higher levels of protein carbonyls in the MCI inferior parietal lobule (IPL) relative to PCAD (and controls), despite equal levels of neuropathology. Proteomics analysis of the IPL revealed differences in protein levels and specific carbonylation that are consistent with preservation of memory in PCAD and apparent memory decline in MCI. Our data suggest that marked changes occur at the protein level in MCI that may cause or reflect memory loss and other AD symptoms.
INTRODUCTION
Alzheimer's disease (AD) affects more than 5 million Americans. This disease progresses phenotypically by slight memory complaints initially, and culminates in the development of dementia. An intermediate stage between cognitively normal individuals and persons with AD is mild cognitive impairment (MCI). Persons with amnestic MCI have memory loss but normal activities of daily living and demonstrate AD-like pathology [1] . AD is characterized pathologically by senile plaques (SPs), neurofibrillary tangles (NFTs), and synapse loss. SPs are composed of amyloid-␤ peptide (A␤), surrounded by numerous protein and dystrophic neurites, while NFTs are composed of hyperphosphorylated tau deposits. Both plaques and tangles are a requirement for the definite diagnosis of AD in concert with apparent signs of memory impairment and/or dementia. A␤ is produced via the amyloidogenic pathway involving beta and gamma secretase-mediated enzymatic cleavage of the amyloid-␤ protein precursor (A␤PP) [2] [3] [4] , resulting in the formation of the 42-amino acid fragment. A␤ is thought to be the most toxic form of A␤, particularly upon oligomerization [5] [6] [7] [8] [9] .
As mentioned previously, SPs, NFTs, and dementia are all requirements for complete antemortem diagnosis of AD. Interestingly, brains from a number of cognitively intact individuals at autopsy reveal an extensive SP and NFT load. Therefore, the possibility of a preclinical or presymptomatic disease state exists [10] [11] [12] . Following accepted criteria [10] and similar to our previous report on preclinical AD (PCAD) [13] , we have defined PCAD as those individuals with sufficient AD pathological alterations to meet National Institute on Aging-Reagan Institute (NIA-RI) intermediate or, rarely, high likelihood criteria (Braak stage III or higher and moderate or frequent neuritic plaque scores) for diagnosis of AD, but who had normal cognitive function as shown by antemortem psychometric test scores within the normal range after adjustment for age and education. Literature on these individuals is limited, most likely due to the rarity of sample availability; however, in addition to significant levels of pathological hallmarks and no observable behavioral/memory problems, other anatomical/biochemical features of PCAD include neuronal hypertrophy [11] , no hippocampal cell loss [14] , increased synaptic plasticity [15] , and alterations in zinc transporters [16] .
Proteomics has been used extensively in our laboratory to identify differentially regulated and oxidatively modified proteins in AD brain [17] . Proteomicsdetermined differences in proteins in AD brain as well as mouse models thereof have provided valuable insight into regulation or disruption of biological pathways contributing to neurodegeneration. In the current study, we used redox proteomics to compare the inferior parietal lobule (IPL) proteome from groups of subjects with equivalent levels of AD-like pathology who differed in their respective clinical symptoms. IPL samples from MCI (AD pathology, behavior/memory impairment) subjects were compared to IPL from PCAD (AD pathology, no behavior/memory impairment) and healthy controls (no AD pathology, no behavior/memory impairment) to examine biochemical differences at the protein level which may shed light into mechanisms underlying memory dysfunction in AD.
METHODS

Participants
MCI, PCAD, and control brains
IPL samples were obtained from 6 patients with MCI, 12 individuals with PCAD, and 12 age-matched individuals who were cognitively intact without postmortem neuropathologic changes of AD (controls). The Rapid Autopsy Program at the University of Kentucky Alzheimer's Disease Research Center (UK ADRC) obtained samples with extremely short postmortem intervals (PMI) ( Table 1) . A short PMI is advantageous in proteomics studies using human tissue since PMI related artifacts are minimized and results more likely reflect the intrinsic situation in PCAD and MCI brain.
All participants underwent annual mental status testing and annual physical and neurological exams, as a part of the UK ADC normal volunteer longitudinal aging study, and did not have a history of dementia or other neurologic disorders. All control and PCAD participants had test scores in the normal range. Neu- 
Treatment of samples
Brain samples for oxidative stress analyses and proteomics were homogenized and suspended in Media I buffer containing protease inhibitors: leupeptin (0.5 mg/mL), pepstatin (0.7 g/mL), and aprotinin (0.5 g/mL). Homogenates were centrifuged at 2000× g for 5 min to remove debris. Protein concentration was determined by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA).
Protein carbonyl assay
Samples (5 l), 12% SDS (5 l), and 10 l of 10 times-diluted 2,4-dinitrophenylhydrazine (DNPH) from a 200 mM stock solution were incubated at room temperature for 20 min, followed by neutralization with 7.5 l neutralization solution (2 M Tris in 30% glycerol). This neutralized solution (250 ng protein) was loaded in each well on a nitrocellulose membrane under vacuum using a slot-blot apparatus. The membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 for 3 h and incubated with a 1 : 100 dilution of anti-DNP polyclonal antibody in PBS containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 for 2 h. The membrane was washed three times in PBS following primary antibody incubation at intervals of 5 min each. The membrane was then incubated following washing with an anti-rabbit IgG alkaline phosphatase-linked secondary antibody diluted in PBS in a 1 : 8000 ratio for 1 h. The membrane was washed three times in PBS for 5 min and developed in Sigmafast tablets [5- 
Two-dimensional gel electrophoresis
Protein samples (250 g) were derivatized with 4 times volume of 10 mM DNPH for western blots or 2N HCl for 2D gels and precipitated by adding ice-cold 100% trichloroacetic acid (TCA) to a final concentration of 15% for 10 min on ice. Precipitates were centrifuged for 2 min at 14,000× g at 4 • C. The pellet was retained and washed three times with 1 ml of 1 : 1 (v/v) ethyl acetate/ethanol. The final pellet was dissolved in rehydration buffer (8 M urea, 2 M thiourea, 2% CHAPS, 0.2% (v/v) biolytes, 50 mM dithiothreitol (DTT), and bromophenol blue). Samples were sonicated in 15 s intervals three times each.
Two-dimensional polyacrylamide gel electrophoresis was performed with a Bio-Rad IEF Cell system using 110-mm pH 3-10 immobilized pH gradients (IPG) strips and Criterion 8-16% resolving gels. IPG strips were actively rehydrated at 50 V 20 • C followed by isoelectric focusing: 300 V for 2 h linear gradient, 1200 V for 4 h slow gradient, 8000 V for 8 h linear gradient, and 8000 for 10 h rapid gradient. Gel strips were equilibrated for 10 min prior to second-dimension separation in solution A [0.375 M Tris-HCl (pH 8.8), 6 M urea (Bio-Rad, Hercules, CA), 2% (w/v) sodium dodecyl sulfate (SDS), 20% (v/v) glycerol, and 0.5% dithiothreitol (DTT, Bio-Rad, Hercules, CA)], and then re-equilibrated for 10 min in solution A containing 4.5% iodoacetamide (IA) instead of DTT. Control PCAD, and MCI strips were placed on the 8-16% Criterion gels, unstained molecular standards were applied, and electrophoresis was performed at 200 V for 65 min.
SYPRO Ruby staining
Gels were fixed in a solution containing 10% (v/v) methanol, 7% (v/v) acetic acid for 40 min and stained overnight at room temperature with agitation in 50 ml of SYPRO Ruby gel stain (Bio-Rad, Hercules, CA, USA). Gels were then destained with 50 ml deionized water overnight.
Western blotting
For 2D western blotting, gels of derivatized samples were transferred to a nitrocellulose membrane 90 mA/gel for 2 h and blocked for 2 h with 3% bovine serum albumin (BSA) in wash blot. Blots were incubated with primary rabbit anti-DNP anti-body (1 : 200) for 2 h. Membranes were washed three times in wash blot and incubated for 1 h with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in wash blot in a 1 : 8000 ratio. The membrane was washed three times in wash blot for 5 min and developed using SigmaFast tablets (5-bromo-4-chloro-3-indoylphosphate/nitroblue tetrazolium, BCIP/NBT substrate). Membranes were dried overnight and scanned for PD-Quest analysis.
Analysis of 2D images
Images from SYPRO Ruby stained gels, used to measure protein content, were obtained using a phosphorimager (excitation = 470 nm, emission = 618 nm, Molecular Dynamics, Sunnyvale, CA, USA). PDQuest 2-D Analysis Software (Bio-Rad) was used to match and analyze visualized protein spots among differential gels and blots. Spot intensities were normalized relative to total density of spots in corresponding gel or blot to correct for slight differences in staining and/or loading. Specific carbonylation of proteins was assessed by dividing the normalized blot intensity of spot by the normalized gel intensity of the corresponding spot in each sample. After completion of spot matching, the densitometric and specific carbonylation values from individual 2D images were compared between groups using statistical analysis. Method reproducibility was assessed by performing 4 gels from a sample and completing spot matching to estimate analytical variance. After completion of spot matching from this same-sample set, an average %CV value of 12% was obtained. All reported proteins in this paper had fold changes much greater than this value to eliminate the possibility that methodological variance is responsible for observed protein changes.
In-gel digestion
Samples were prepared according to the method described by Thongboonkerd et al. [18] . Briefly, the protein spots were cut and removed from the gel with a clean razor blade. The gel pieces were placed into individual, clean 1.5 ml microcentrifuge tubes and kept overnight at −20 • C. The gel pieces were thawed and washed with 0.1 M ammonium bicarbonate (NH 4 HCO 3 ) (Sigma) for 15 min at room temperature. Acetonitrile (Sigma) was added to the gel pieces and incubated for an additional 15 min. The liquid was removed and the gel pieces were allowed to dry. The gel pieces were rehydrated with 20 mM DTT (BioRad, Hercules, CA, USA) in 0.1 M NH 4 HCO 3 (Sigma) and incubated for 45 min at 56 • C. The DTT was removed and replaced with 55 mM IA (Bio-Rad) in 0.1 M NH 4 HCO 3 for 30 min in the dark at room temperature. The liquid was drawn off and the gel pieces were incubated with 50 mM NH 4 HCO 3 at room temperature for 15 min. Acetonitrile was added to the gel pieces for 15 min at room temperature. All solvents were removed and the gel pieces were allowed to dry for 30 min. The gel pieces were rehydrated with addition of a minimal volume of 20 ng/l modified trypsin (Promega, Madison, WI, USA) in 50 mM NH 4 HCO 3 . The gel pieces were chopped and incubated with shaking overnight (∼18 h) at 37 • C.
Mass spectrometry
Tryptic peptides were analyzed with an automated nanospray Nanomate (Advion Biosystems) Orbitrap XL MS (ThermoFinnigan) platform. The Orbitrap MS was operated in a data-dependent mode whereby the 8 most intense parent ions measured in the FT at 60,000 resolution were selected for ion trap fragmentation with the following conditions: injection time 50 ms, 35% collision energy, MS/MS spectra were measured in the FT at 7500 resolution, and dynamic exclusion was set for 120 seconds. Each sample was acquired for a total of ∼2.5 min. MS/MS spectra were searched against the International Protein Index (IPI). Human Database using SEQUEST and search results were filtered with the following criteria: Xcorr > 1.5, 2.0, 2.5, 3.0 for +1, +2, +3, and +4 charge states, respectively, Cn > 0.1, and p-value (protein and peptide) <0.01. IPI accession numbers were cross-correlated with SwissProt accession numbers for final protein identification.
Statistical analysis
For patient data and slot blot data, one-way ANOVA followed by Newman-Keuls post hoc test was used to assess statistical significance. For proteomics data, Mann-Whitney U test was used for significance. p values less than 0.05 were considered statistically significant.
RESULTS
Global oxidative stress in MCI IPL
Oxidative modifications to proteins have been implicated in the pathology and progression of AD [17, [19] [20] [21] [22] [23] [24] [25] [26] [27] . Several reports from our laboratory have also shown elevations in oxidative damage in several brain regions in MCI, including (but not limited to) the IPL. In the current study, we observed consistent findings with previous reports showing increased oxidative damage in MCI IPL as assessed by protein carbonyls (p < 0.01, Fig. 1 ). Furthermore, a significant increase in protein carbonyls was observed in MCI relative to PCAD (p < 0.01), despite equal levels of AD neuropathology. Consistent with our previous report and others examining levels of protein carbonyls in PCAD relative to controls [13, 28] we observed no significant differences between these two groups (Fig. 1) .
Proteomics determined differences in protein levels distinguishing PCAD from MCI
Two dimensional gel-based proteomics has been used extensively to examine differences in protein levels in AD brain, MCI brain, and transgenic mouse models of AD [17] . Oftentimes, proteomicsdetermined alterations in levels of proteins are indicative of up-regulation or down-regulation of pathways involved in disease pathogenesis or response to a given treatment. Therefore, we performed gelbased proteomics (Fig. 2) to investigate differences in protein expression in conditions with equal pathological levels (PCAD and MCI) with differing clinical symptoms. Interestingly, 6 proteins were observed to $ Peptide hits represents total number of peptides matches, while number in parentheses represents number of unique sequences identified; @ MW = molecular weight, in kDa; pI = isoelectric point; ∧ TRMBL no; # refers to probability associated with SEQUEST score. have decreased levels in MCI relative to both PCAD and control IPL, while 2 proteins showed significant increases in MCI IPL relative to both PCAD and controls. One protein (Cu, Zn superoxide dismutase (Cu, Zn SOD)), displayed a significant increase in PCAD relative to both control and MCI IPL.
Proteins whose levels were unchanged in PCAD versus control, but show a significant increase in MCI relative to both of these groups were identified as albumin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Tables 2a-c, Fig. 3 ). Conversely, proteins that showed no significant differences in Fig. 3 . Enhanced 2D images clearly showing differences in protein levels reported in Table 2. levels between PCAD and control, but show a significant decrease in MCI IPL relative to both groups were identified as ubiquitin carboxy-terminal hydrolase 1 (UCHL1), dihydrolipoyl dehydrogenase (DHD), ATP synthase, elongation factor Tu (EfTu), phosphatidylethanolamine binding protein 1 (PEBP1), and pyruvate kinase (PK) (Tables 2a-c, Fig. 3 ). Several of these proteins have been implicated in AD-related cell death and memory impairment in previous independent studies. The alterations observed here may provide insight into the connection between pathology and biochemical events/pathways as they relate to memory.
Redox proteomics analysis of MCI IPL compared to PCAD for carbonylated proteins
Reactive oxygen species (ROS) or reactive nitrogen species (RNS) are capable of causing oxidative modifications to proteins, lipids, nucleic acids, and carbohydrates. Identification of specific targets of oxidation can shed light on dysfunctional biochemical processes/pathways in a disease state, as increased oxidation or nitration is typically met with compromised function. Therefore, we employed 2-D redox proteomics in order to identify which proteins in MCI brain undergo specific carbonylation relative to PCAD.
As with any redox proteomics experiment investigating modified proteins, there exists the possibility that some excessively oxidized proteins can become cross-linked and, therefore, unable to be solubilized under SDS-PAGE conditions [29] . Therefore, observed changes in relative carbonyl content of the reported proteins are restricted to those proteins whose extent of carbonylation is measurable given the current solubility conditions.
We observed significant increases in the specific carbonyl levels of alpha enolase and heat shock protein 90 (HSP90) in MCI IPL relative to PCAD (p < 0.05) (Tables 3a-c, Fig. 4) . Furthermore, HSP90 was also shown to be increasingly oxidized in MCI relative to control (p < 0.05) (Fig. 4) . No significant differences in local carbonylation were observed between PCAD and control groups, further supporting our finding here (and elsewhere) that oxidative stress is absent from PCAD brain, possibly corresponding to cellular preservation and protection from memory impairment.
DISCUSSION
Pathologically, AD is indexed by SPs and NFTs. SPs are composed primarily of A␤, a peptide thought to be a contributing factor to neurodegeneration; this is controversial, as a small percentage of cognitively $ Peptide hits represents total number of peptides matches, while number in parentheses represents number of unique sequences identified; @ MW=molecular weight, in kDa; pI = isoelectric point; # refers to probability associated with SEQUEST score. 
Table 3c
General trends of proteins observed as exhibiting differences in specific oxidation between control, PCAD, and MCI intact individuals at autopsy have significant levels of plaque and tangle pathology that would otherwise warrant diagnosis of AD, or at least, MCI. A␤ has been shown to cause oxidative stress, both in AD and MCI brain, and in mouse models of AD [17, 19, 20] . However, in our previous report on PCAD, we observed no significant differences in global oxidative stress relative to controls, possibly due to a lack of oligomerization of A␤ [13] . Others also observed no differences in protein carbonyls in PCAD hippocampus, superior and medial temporal gyrus, and cerebellum [28] . Furthermore, in the current study, we confirm this result in the IPL, and also, observed no significant differences in local carbonylation of proteins in PCAD compared to control (as assessed by 2D redox proteomics). Because oxidative imbalance in a cell can lead to adverse protein and lipid modifications culminating in apoptosis, an absence of significant oxidative stress in PCAD may be central to the lack of cell loss [14] , as well as the neuronal hypertrophy [11] and increased synaptic plasticity [15] observed in previous reports of PCAD.
In this study, we chose to compare PCAD to MCI instead of AD due to the fact that PCAD patients typically displayed MCI-like levels of pathology, with no observable memory impairment (Table 1) . Therefore, the proteomics-determined differences in protein levels and oxidative modifications to proteins between two groups that display equal levels of AD pathology, but differ in clinical manifestations of memory impairment, provide valuable insight into the connection between pathology and symptoms. Proteomics has been used extensively by our lab to identify differences in protein levels and oxidative modifications to proteins in AD and MCI brain as well as mouse models of AD [17] . Because oxidative modification to proteins typically results in lowered functionality, identification of modified proteins may be indicative of dysfunctional cellular processes in AD. Also, differential levels of proteins in a diseased versus control comparison often shed insight into pathways or mechanisms that are upor downregulated, possibly contributing to or acting against an inherent insult.
Initial studies on brains of AD subjects observed increased protein carbonylation in AD subjects relative to controls [30] . Our group showed that brain protein oxidation in AD occurred in regions rich in A␤, but not in A␤-poor cerebellum [31] . Other reports have also observed increased carbonyls in AD brain [31] , as well as increases in the specific carbonyl content of several proteins [24, 32, 33] . This modification has been suggested to underlie the reduced activity of several proteins whose function is diminished in AD [34] . The appearance of increased protein carbonylation in AD is evident in brain areas such as hippocampus [24, 30, 35, 36] , and IPL [32, 33] , both of which are memory-associated regions. Furthermore, in brain regions not associated with memory/cognition, such as cerebellum, protein carbonylation is largely absent [31, 35] . Therefore, increased levels of protein carbonylation leading to decreased enzymatic activity, loss of functional processes and, eventually, neuronal death, have been proposed as a possible driving force of AD pathogenesis [30] .
Between PCAD and MCI, we observe a significant increase in the level of protein carbonyls in MCI, indicative of significantly elevated oxidative stress in MCI despite equal levels of pathology. We also found significantly higher protein carbonyl levels in MCI relative to control, confirming previous reports on increased protein oxidation in MCI [20, 21, 37] . Consistent with this observation, we have shown altered levels and activities of antioxidant enzymes in brains of AD/MCI patients relative to healthy controls [26] . In the present study, we observed differences in the levels of Cu, Zn SOD and DHD between the three groups using 2D proteomics. Cu, Zn SOD showed a significant increase in PCAD relative to control and MCI, while DHD was significantly lower in MCI relative to PCAD and control. Cu, Zn SOD is a cytosolic antioxidant that catalyzes the dismutation of superoxide to hydrogen peroxide; this protein has been previously observed to highly correlate with memory and increased black/white reversal learning in a canine study of aging [38] . Other groups have observed decreased DHD in AD brain relative to healthy controls [39] ; here we replicate this finding in MCI IPL, but also observe that the level of this protein is significantly suppressed in MCI relative to PCAD as well, while no difference was observed between PCAD and control. DHD is the E3 subunit of the enzyme pyruvate dehydrogenase, and, more specifically, is involved in the oxidation-reduction of lipoic acid for the (eventual) production of NADH. A deficiency in DHD, a critical subunit of pyruvate dehydrogenase, may be responsible for the decreased activity of this complex observed in brains of AD patients in another study [40] .
Glucose metabolizing enzymes have been reported to be differentially expressed in many previous studies of AD. The observation of aberrant levels of proteins involved in glycolysis/TCA cycle/electron transport is thought to cause or contribute to the observed decrease in glucose metabolism as evidenced by PET scanning in brains of AD patients [41] . Because depletion of cellular ATP production via mitochondria can lead to cell death, a key event in AD pathogenesis, it is thought that these events are interrelated. Here, we observe a significant increase in GAPDH in MCI relative to PCAD and controls, and a significant decrease in pyruvate kinase and ATP synthase in MCI relative to PCAD and controls. ATP synthase has been observed to be decreased in AD hippocampus [42] , and beta subunit mRNA for this protein has also been reported to be decreased [43] . PK converts phosphoenolpyruvate to pyruvate and ATP in the final step of glycolysis; lower levels of this enzyme may reduce cellular ATP levels critical for maintaining neuronal survival. Additionally, we observed a significant increase in the carbonylation status of ENO1 in MCI compared to PCAD, despite an equal level of AD pathology. Oxidative damage to glycolytic enzymes has been previously observed to lower function, as observed previously [44] . In addition to adversely affecting its glycolytic activity, oxidative modification to enolase and the subsequent functional alteration may also affect its multitude of other functions, as enolase is also a neurotrophic factor, 14-3-2 [45] [46] [47] , a hypoxic stress protein [48] , c-Myc binding protein and transcription factor [49, 50] , and a strong plasminogen binding protein [51, 52] . Furthermore, many of these non-glycolytic functions have been implicated in AD [53, 54] .
Cells utilize proteasomes to break down aberrantly folded or damaged proteins. Proteins that are incorrectly folded can trigger a heat shock response, leading to the induction of intracellular heat shock proteins (HSP). Therefore, dysfunction in the heat shock response/ubiquitin/proteasomal pathways can lead to intracellular buildup of damaged biomolecules that can lead to the death of the cell. We observed a significant increase in the specific carbonylation of HSP 90 in MCI relative to PCAD and control. Furthermore, previous reports have shown a downregulation of UCHL1 in AD brain compared to controls [55] ; here, we observe lower levels of this protein in MCI relative to both control and PCAD. Based on this data, we suggest an imbalance in the proteasomal network in MCI (that is absent in PCAD), leading to a buildup of aberrantly folded proteins, possibly contributing to memory loss and neuropathological changes in MCI. Further, HSP90 is critical to suppressing inflammation through degradation of hypoxic-inducing factor 1 alpha [56] ; oxidation of this protein may contribute to the rampant brain-resident inflammation in AD/MCI.
Other proteins whose levels were found to differ in MCI relative to PCAD and control were albumin, PEBP1, and EF-Tu. Albumin in brain/cerebrospinal fluid is indicative of blood brain barrier (BBB) dysfunction [57] , and an increase in the level of this protein in MCI relative to PCAD and control may indicate BBB breakdown as the AD phenotype develops. Eftu has been previously shown to be HNE-bound in MCI brain by our laboratory [23] ; here we observed decreased levels of this protein in MCI, possibly indicating a decrease in tRNA transport from the cytosol to the ribosome for cytosolic protein production. Lastly, PEBP, or neuropolypeptide h3, has been implicated in AD [58, 59] , due to its involvement in the production of choline acetyltransferase, a critical enzyme in acetylcholine synthesis; decreased levels of this protein in MCI IPL relative to PCAD and controls potentially signal decreased acetylcholine production as has been previously reported in AD. In fact, one of the most commonly prescribed classes of drugs to treat AD on the market today is the acetylcholinesterase inhibitors, implicating decreased acetylcholine levels as a major pathogenic event in AD. A lack of significant alteration of PEBP1 in PCAD versus control IPL may infer that levels of this enzyme are sufficient to maintain acetylcholine levels to preserve memory.
In closing, the data presented here are supportive of the notion that in PCAD there is a relatively protective period against AD-related neurodegeneration, which as oxidative stress increases in MCI, is lost. The fact that some adverse changes in protein modifications and protective protein levels observed here correlate with clinical manifestations of AD supports previous studies that posit that these changes are critical to memory impairment. The observed changes in oxidative stress and protein levels in MCI relative to PCAD in this study may help explain previous studies that observed significant neuron loss in very mild dementia of the AD type that was absent in PCAD [14, 60, 61] . A large caveat to working with PCAD is whether or not these individuals would have developed the AD phenotype had they lived long enough; nevertheless, our data further support the concept of PCAD, and highlight considerable differences at the protein level between PCAD and MCI, despite equal levels of pathology.
